ZomedicaZOM
ZOM
About: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
Employees: 144
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.36% less ownership
Funds ownership: 8.88% [Q2] → 8.52% (-0.36%) [Q3]
10% less capital invested
Capital invested by funds: $12.3M [Q2] → $11.1M (-$1.24M) [Q3]
12% less funds holding
Funds holding: 95 [Q2] → 84 (-11) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
Research analyst outlook
We haven’t received any recent analyst ratings for ZOM.
Financial journalist opinion
Neutral
Accesswire
2 weeks ago
Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market
License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States. Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.
Neutral
Accesswire
4 weeks ago
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
With the addition of these two new assay launches, Zomedica has added 8 new assays in the past 18 months to the rapidly growing TRUFORMA Platform ANN ARBOR, MI / ACCESSWIRE / December 23, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform. Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum.
Neutral
Accesswire
1 month ago
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025.
Neutral
Accesswire
1 month ago
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present and host one-on-one meetings with investors at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 4, 2025 at 11:00 am Eastern Standard Time. A high-definition video webcast of the presentation will be available the following day on the Company's website, www.zomedica.com, and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website, www.nobleconference.com, and on the investor portal created by Noble, Channelchek at www.channelchek.com.
Neutral
Accesswire
2 months ago
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. Veterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dysfunction (PPID), with prevalence reported between 18-27% of ponies and horses.
Neutral
Accesswire
2 months ago
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
ANN ARBOR, MI / ACCESSWIRE / November 12, 2024 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer, as well as news and advanced market data on Zomedica Corp., is available on Channelchek.
Neutral
Accesswire
2 months ago
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
ANN ARBOR, MI / ACCESSWIRE / November 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Micro Cap Conference, taking place on November 13-14, 2024. The presentation will begin at 11:30 ET on November 14, 2024 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_bYqPwu5jRaODxkG5UNkqNg Zomedica will also host virtual one-on-ones with investors on Thursday, November 14, 2024.
Neutral
Seeking Alpha
2 months ago
Zomedica Corp. (ZOM) Q3 2024 Earnings Call Transcript
Zomedica Corp. (NYSE:ZOM ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Larry Heaton – Chief Executive Officer Mike Zuehlke – Vice President and Corporate Controller Conference Call Participants Robert LeBoyer – Noble Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to the Zomedica Q3 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode.
Neutral
Accesswire
2 months ago
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024. "We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit increase compared to last year, which demonstrates that the execution of our growth initiatives has continued to pay dividends.
Neutral
Accesswire
2 months ago
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
New Ear Cytology protocol significantly improves veterinary practice workflow by reducing total time to perform common diagnostic procedure ANN ARBOR, MI / ACCESSWIRE / October 24, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the release of the Ear Cytology Quick Scan protocol, a new feature available on the TRUVIEW microscope equipped with the TRUprep™ automated slide preparation system. This innovative feature streamlines the slide preparation and scanning of ear cytology cases, allowing veterinary professionals to diagnose and treat companion animals faster and more efficiently.
Charts implemented using Lightweight Charts™